Britta Weber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Britta Weber has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Rahbek Mortensen
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus 8200, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus 8200, Denmark
3 shared publications Katherine Paton
3 shared publicationsRoy Ma
3 shared publicationsAdrian T. Fung
2 shared publicationsAlexandra Villa-Forte
2 shared publicationsAndrea Flühs
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in Physica Medica
- Vol. 147, 105830
Respiratory gated proton therapy for liver cancer: Setup and gating validation based on fiducial marker motion extracted from 2D kV projection images acquired during cone-beam CT
- 3 June 2026
- Published by Elsevier in Physica Medica
- Vol. 147, 105830
Open AccessRespiratory gated proton therapy for liver cancer: Setup and gating validation based on fiducial marker motion extracted from 2D kV projection images acquired during cone-beam CT
- Open Access
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Reply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Open AccessReply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- Open Access
- 5 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1048-1056
Cholangiocarcinoma in Denmark: time trends in mortality following resection
Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time trends in mortality risk after resection in a nationwide Danish cohort. Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004–2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two. We computed the proportions of patients who received downstaging or adjuvant chemotherapy, and we estimated age- and sex-adjusted mortality risks. Results: Between 2004 and 2022, 611 patients with cholangiocarcinoma underwent resection (13% of 4572 patients with cholangiocarcinoma). The proportion who underwent resection increased from 9% in 2004–2012 to 16% in 2018–2022, the median age of resected patients rose from 65 to 69 years, and the proportion with comorbidities increased from 17% to 28%. In patients who underwent liver resection, the proportion who had received downstaging chemotherapy increased from P -value = 0.37). In patients who underwent biliary tract resection, only 3% received downstaging chemotherapy, but the proportion who received adjuvant therapy increased from 17% (10–29) in 2004–2012 to 59% (48–68) in 2018–2022. Even so, these patients’ age- and sex-adjusted mortality remained stable (1-year mortality ranging from 19% to 24%, P -value = 0.34). Conclusion: The proportion of patients with cholangiocarcinoma who underwent liver or biliary tract resection increased, and more patients received downstaging chemotherapy and adjuvant chemotherapy. Nonetheless, age- and sex-adjusted mortality risks remained constant. The explanations for this pattern are unclear but likely involve changing patient characteristics other than age and sex.
- 5 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1048-1056
Open AccessCholangiocarcinoma in Denmark: time trends in mortality following resection
Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time trends in mortality risk after resection in a nationwide Danish cohort. Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004–2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two. We computed the proportions of patients who received downstaging or adjuvant chemotherapy, and we estimated age- and sex-adjusted mortality risks. Results: Between 2004 and 2022, 611 patients with cholangiocarcinoma underwent resection (13% of 4572 patients with cholangiocarcinoma). The proportion who underwent resection increased from 9% in 2004–2012 to 16% in 2018–2022, the median age of resected patients rose from 65 to 69 years, and the proportion with comorbidities increased from 17% to 28%. In patients who underwent liver resection, the proportion who had received downstaging chemotherapy increased from P -value = 0.37). In patients who underwent biliary tract resection, only 3% received downstaging chemotherapy, but the proportion who received adjuvant therapy increased from 17% (10–29) in 2004–2012 to 59% (48–68) in 2018–2022. Even so, these patients’ age- and sex-adjusted mortality remained stable (1-year mortality ranging from 19% to 24%, P -value = 0.34). Conclusion: The proportion of patients with cholangiocarcinoma who underwent liver or biliary tract resection increased, and more patients received downstaging chemotherapy and adjuvant chemotherapy. Nonetheless, age- and sex-adjusted mortality risks remained constant. The explanations for this pattern are unclear but likely involve changing patient characteristics other than age and sex.
- Open Access
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Recommendations for radiotherapy quality assurance in clinical trials
- 22 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 209, 110950
Open AccessRecommendations for radiotherapy quality assurance in clinical trials
- Open Access
- 30 September 2024
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 24 (2) , 286-302
Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
Backgrounds/Aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.
- 30 September 2024
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 24 (2) , 286-302
Open AccessRecent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
Backgrounds/Aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.
- Open Access
- 18 July 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (7) , 6820-6837
Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials
Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult. Systemic chemotherapy has been an established part of the standard treatment in patients with both locally advanced and metastatic pancreatic cancer. In contrast, the use of radiotherapy has no clear defined role in the treatment of these patients. With the evolving imaging and radiation techniques, radiation could become a plausible intervention. In this review, we give an overview over the available data regarding radiotherapy, chemoradiation, and stereotactic body radiation therapy. We performed a systematic search of Embase and the PubMed database, focusing on studies involving locally advanced pancreatic cancer (or non-resectable pancreatic cancer) and radiotherapy without any limitation for the time of publication. We included randomised controlled trials involving patients with locally advanced pancreatic cancer, including radiotherapy, chemoradiation, or stereotactic body radiation therapy. The included articles represented mainly small patient groups and had a high heterogeneity regarding radiation delivery and modality. This review presents conflicting results concerning the addition of radiation and modality in the treatment regimen. Further research is needed to improve outcomes and define the role of radiation therapy in pancreatic cancer.
- 18 July 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (7) , 6820-6837
Open AccessRadiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials
Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult. Systemic chemotherapy has been an established part of the standard treatment in patients with both locally advanced and metastatic pancreatic cancer. In contrast, the use of radiotherapy has no clear defined role in the treatment of these patients. With the evolving imaging and radiation techniques, radiation could become a plausible intervention. In this review, we give an overview over the available data regarding radiotherapy, chemoradiation, and stereotactic body radiation therapy. We performed a systematic search of Embase and the PubMed database, focusing on studies involving locally advanced pancreatic cancer (or non-resectable pancreatic cancer) and radiotherapy without any limitation for the time of publication. We included randomised controlled trials involving patients with locally advanced pancreatic cancer, including radiotherapy, chemoradiation, or stereotactic body radiation therapy. The included articles represented mainly small patient groups and had a high heterogeneity regarding radiation delivery and modality. This review presents conflicting results concerning the addition of radiation and modality in the treatment regimen. Further research is needed to improve outcomes and define the role of radiation therapy in pancreatic cancer.
- 9 October 2021
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (11) , 1548-1554
A national study on the inter-observer variability in the delineation of organs at risk in the brain
The Danish Neuro Oncology Group (DNOG) has established national consensus guidelines for the delineation of organs at risk (OAR) structures based on published literature. This study was conducted t...
- 9 October 2021
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (11) , 1548-1554
A national study on the inter-observer variability in the delineation of organs at risk in the brain
The Danish Neuro Oncology Group (DNOG) has established national consensus guidelines for the delineation of organs at risk (OAR) structures based on published literature. This study was conducted t...
- 25 October 2020
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 55 (12) , 1433-1440
TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associ...
- 25 October 2020
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 55 (12) , 1433-1440
TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associ...
- 1 July 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 63 (14) , 145010
Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy
The accuracy of stereotactic body radiotherapy (SBRT) in the liver is limited by tumor motion. Selection of the most suitable motion mitigation strategy requires good understanding of the geometric and dosimetric consequences. This study compares the geometric and dosimetric accuracy of actually delivered respiratory gated SBRT treatments for 15 patients with liver tumors with three simulated alternative motion adaptation strategies. The simulated alternatives are MLC tracking, baseline shift adaptation by inter-field couch corrections and no intrafraction motion adaptation. The patients received electromagnetic transponder-guided respiratory gated IMRT or conformal treatments in three fractions with a 3–4 mm gating window around the full exhale position. The CTV-PTV margin was 5 mm axially and 7–10 mm cranio-caudally. The CTV and PTV were covered with 95% and 67% of the prescribed mean CTV dose, respectively. The time-resolved target position error during treatments with the four investigated motion adaptation strategies was used to calculate motion margins and the motion-induced reduction in CTV D 95 relative to the planned dose (Δ D 95 ). The mean (range) number of couch corrections per treatment session to compensate for tumor drift was 2.8 (0–7) with gating, 1.4 (0–5) with baseline shift adaptation, and zero for the other strategies. The motion margins were 3.5 mm (left–right), 9.4 mm (cranio–caudal) and 3.9 mm (anterior–posterior) without intrafraction motion adaptation, approximately half of that with baseline shift adaptation, and 1–2 mm with MLC tracking and gating. With 7 mm CC margins the mean (range) of Δ D 95 for the CTV was 8.1 (0.6–29.4)%-points (no intrafraction motion adaptation), 4.0 (0.4–13.3)%-points (baseline shift adaptation), 1.0 (0.3–2.2)%-points (MLC tracking) and 0.8 (0.1–1.8)%-points (gating). With 10 mm CC margins Δ D 95 was instead 4.8 (0.3–14.8)%-points (no intrafraction motion adaptation) and 2.9 (0.2–9.8)%-points (baseline shift adaptation). In conclusion, baseline shift adaptation can mitigate gross dose deficits without the requirement of real-time motion adaptation. MLC tracking and gating, however, more effectively ensure high similarity between planned and delivered doses.
- 1 July 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 63 (14) , 145010
Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy
The accuracy of stereotactic body radiotherapy (SBRT) in the liver is limited by tumor motion. Selection of the most suitable motion mitigation strategy requires good understanding of the geometric and dosimetric consequences. This study compares the geometric and dosimetric accuracy of actually delivered respiratory gated SBRT treatments for 15 patients with liver tumors with three simulated alternative motion adaptation strategies. The simulated alternatives are MLC tracking, baseline shift adaptation by inter-field couch corrections and no intrafraction motion adaptation. The patients received electromagnetic transponder-guided respiratory gated IMRT or conformal treatments in three fractions with a 3–4 mm gating window around the full exhale position. The CTV-PTV margin was 5 mm axially and 7–10 mm cranio-caudally. The CTV and PTV were covered with 95% and 67% of the prescribed mean CTV dose, respectively. The time-resolved target position error during treatments with the four investigated motion adaptation strategies was used to calculate motion margins and the motion-induced reduction in CTV D 95 relative to the planned dose (Δ D 95 ). The mean (range) number of couch corrections per treatment session to compensate for tumor drift was 2.8 (0–7) with gating, 1.4 (0–5) with baseline shift adaptation, and zero for the other strategies. The motion margins were 3.5 mm (left–right), 9.4 mm (cranio–caudal) and 3.9 mm (anterior–posterior) without intrafraction motion adaptation, approximately half of that with baseline shift adaptation, and 1–2 mm with MLC tracking and gating. With 7 mm CC margins the mean (range) of Δ D 95 for the CTV was 8.1 (0.6–29.4)%-points (no intrafraction motion adaptation), 4.0 (0.4–13.3)%-points (baseline shift adaptation), 1.0 (0.3–2.2)%-points (MLC tracking) and 0.8 (0.1–1.8)%-points (gating). With 10 mm CC margins Δ D 95 was instead 4.8 (0.3–14.8)%-points (no intrafraction motion adaptation) and 2.9 (0.2–9.8)%-points (baseline shift adaptation). In conclusion, baseline shift adaptation can mitigate gross dose deficits without the requirement of real-time motion adaptation. MLC tracking and gating, however, more effectively ensure high similarity between planned and delivered doses.
- Open Access
- 16 September 2015
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 2 (1) , 59
Errata
[This corrects the article DOI: 10.1159/000371555.][This corrects the article DOI: 10.1159/000370151.].
- 16 September 2015
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 2 (1) , 59
Open AccessErrata
[This corrects the article DOI: 10.1159/000371555.][This corrects the article DOI: 10.1159/000370151.].